Sio Gene Therapies Inc. buy tamam
Start price
31.08.17
/
50%
€143.67
Target price
09.01.18
€144.32
Performance (%)
-88.37%
End price
09.01.18
€16.71
Summary
This prediction ended on 09.01.18 with a price of €16.71. The BUY prediction by tamam for Sio Gene Therapies Inc. performed very badly with a performance of -88.37%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Sio Gene Therapies Inc. | - | - | - | - |
| iShares Core DAX® | 1.717% | 3.368% | 5.887% | 52.377% |
| iShares Nasdaq 100 | -4.565% | -4.238% | 21.386% | 72.449% |
| iShares Nikkei 225® | -7.120% | -11.869% | 42.357% | 57.579% |
| iShares S&P 500 | -0.894% | 1.687% | 19.495% | 62.154% |
Comments by tamam for this prediction
In the thread Sio Gene Therapies Inc. diskutieren
tamam stimmt der Outperform-Einschätzung der institutionellen Analysten zu
One of the most watched trial results on the horizon is for Intepirdine targeting Alzheimers'. Phase 3 data is out from Axovant Sciences by the end of September. Positive results would trigger a massive rally in the stock. I am not sanguine simply because this disease area has the highest failure rate in the industry.
(Vom Mitglied beendet)